Drug-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Comprehensive Review

0
0
0

Drug-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Comprehensive Review

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune disorders characterized by necrotizing inflammation of small-to-medium vessels and the presence of ANCAs. The condition encompasses microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Drug-induced AAV, a subset of AAV, has gained increasing attention due to its association with diverse pharmacologic agents. This review synthesizes current knowledge on drug-induced AAV, covering its definition, epidemiology, causative drugs, pathogenesis, clinical features, diagnostic approaches, treatment strategies, and prognosis.

Definition and Classification

Drug-induced AAV is defined as vasculitis triggered by medication exposure, characterized by ANCA positivity and histopathological features of small-vessel inflammation. The 2012 International Chapel Hill Consensus Conference categorized drug-induced AAV under “vasculitis associated with probable etiology,” distinguishing it from idiopathic forms. Diagnosis relies on temporal association between drug exposure and symptom onset, resolution after drug discontinuation, and exclusion of alternative causes such as infections or malignancies.

Epidemiology

Epidemiological data on drug-induced AAV remain limited. Prospective studies highlight a median prevalence of 30% for propylthiouracil (PTU)-induced AAV among treated patients, compared to 6% for methimazole (MMI). Case reports and cross-sectional analyses suggest that ANCA positivity precedes clinical symptoms, emphasizing the importance of monitoring in high-risk populations.

Associated Medications

Drug-induced AAV has been linked to multiple drug classes, with anti-thyroid drugs (ATDs) and biologics being the most common culprits:

  1. Anti-Thyroid Drugs (ATDs):

    • PTU: Accounts for >90% of ATD-induced AAV cases. The risk escalates with prolonged use (>18 months), with reports of vasculitis even after 3 years.
    • Methimazole (MMI) and Carbimazole (CMZ): Rarely implicated, with lower prevalence (0–16%).

  2. Biologic Agents:

    • TNF-α Inhibitors (e.g., adalimumab, etanercept): Associated with ANCA-positive vasculitis, likely due to disrupted immune regulation.

  3. Other Agents:

    • Antimicrobials: Minocycline, cefotaxime, nitrofurantoin.
    • Psychotropics: Clozapine, thioridazine.
    • Immunomodulators: Hydralazine, levamisole-adulterated cocaine.
    • Miscellaneous: Allopurinol, isotretinoin, phenytoin.

A notable subset is cocaine/levamisole-associated autoimmune syndrome (CLAAS), where levamisole—a cocaine adulterant—induces ANCA-positive vasculitis and neutropenia.

Pathogenesis

The pathogenesis of drug-induced AAV involves genetic predisposition, epigenetic dysregulation, and neutrophil extracellular traps (NETs):

  1. Genetic Factors:

    • HLA-DP and HLA-DQ polymorphisms are linked to PR3-ANCA and MPO-ANCA specificity, respectively.

  2. Epigenetic Modifications:

    • Hypomethylation of MPO and PRTN3 genes enhances autoantigen expression. Drugs like hydralazine inhibit DNA methylation, promoting autoreactive T-cell activation.

  3. Role of Neutrophil Extracellular Traps (NETs):

    • NETs—composed of chromatin and granule proteins—induce ANCA production via delayed degradation (due to reduced DNase I activity) and antigen exposure.
    • Drug-Specific Mechanisms:
      • PTU: Alters NET structure, masking DNase I recognition sites.
      • Levamisole/Cocaine: Augments B-cell activating factor and NET formation.
      • Hydralazine: Directly induces NET release.

Clinical Features and Differentiation from Primary AAV

Drug-induced AAV mimics primary AAV but exhibits distinct features:

Parameter Drug-Induced AAV Primary AAV
Demographics Younger females (ATD users) Older adults, equal gender distribution
Common Symptoms Cutaneous lesions, arthralgia Fever, weight loss, renal involvement
ANCA Specificity MPO-ANCA predominance MPO-ANCA or PR3-ANCA
Multiple Antibodies Coexisting ANA, anti-histones, anti-β2GP1 Rare
Severity Milder, limited organ involvement More severe, multisystem disease
Prognosis Excellent with drug withdrawal Higher relapse risk, chronic course

Diagnostic Approach

  1. Clinical Criteria:

    • Temporal association with drug exposure.
    • ANCA positivity (MPO-ANCA most common).
    • Exclusion of infections, malignancies, and primary vasculitis.

  2. Laboratory Findings:

    • Elevated creatinine, proteinuria, and C-reactive protein (CRP) are less pronounced than in primary AAV.
    • Multi-ANCA positivity (e.g., anti-lactoferrin, anti-elastase).

  3. Histopathology:

    • Biopsy of affected organs (e.g., kidney, skin) reveals necrotizing vasculitis and pauci-immune glomerulonephritis.

Management Strategies

  1. Immediate Drug Cessation:

    • Sufficient for mild cases without organ involvement.

  2. Immunosuppressive Therapy:

    • Glucocorticoids: Prednisone (1 mg/kg/day) tapered over 1–2 months.
    • Cyclophosphamide: Reserved for severe cases (e.g., alveolar hemorrhage, rapidly progressive glomerulonephritis).
    • Plasmapheresis: For life-threatening conditions (e.g., serum creatinine >5.6 mg/dL).

  3. Prognosis:

    • Most patients achieve remission post-drug withdrawal.
    • Renal recovery is typical unless delayed diagnosis leads to chronic damage.

Conclusion

Drug-induced AAV represents a distinct clinical entity with favorable outcomes upon timely drug discontinuation. Vigilance is essential for high-risk medications like PTU and biologics. Mechanistic insights into NET formation and genetic/epigenetic dysregulation offer potential therapeutic targets. Future research should focus on biomarker discovery and standardized diagnostic protocols to improve early recognition and management.

doi.org/10.1097/CM9.0000000000000539

Was this helpful?

0 / 0